Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations JakaviⓇ - JAK 1/2 inhibitor Study Indication Phase Patients NCT04097821 ADORE (CINC424H12201) Myelofibrosis Phase 1/2 130 Primary Outcome Measures Arms Intervention Incidence of dose limiting toxicities within the first 2 cycles Response rate at the end of cycle 6 Ruxolitinib Ruxolitinib+Siremadlin Ruxolitinib+Crizanlizumab Ruxolitinib+MBG453 Ruxolitinib+LTT462 Ruxolitinib+NIS793 Patients with Myelofibrosis (MF) Target Patients Read-out Milestone(s) Publication 2024 TBD 130 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation